Table 3.

Features of the vaccines against SARS CoV-2 currently available

COVID-19 Vaccine developer/manufacturer	Vaccine platform	Type of candidate vaccine	Number of doses	Timing of doses	Route of Administration
Moderna/NIAID	RNA	LNP-encapsulated mRNA	2	0,28 days	IM
BioNTech/Fosun Pharma/Pfizer	RNA	3 LNP-mRNAs	2	0,28 days	IM
University of Oxford/AstraZeneca	Non-Replicating Viral Vector	replication- deficient chimpanzee adenovirus (ChAdOx1)	2	0, between 4 and 12 weeks apart.	IM
Janssen Pharmaceutical Companies	Non-Replicating Viral Vector	Adenovirus type 26 vector	1	0	IM
Sputnik V (Gam-COVID-Vac	Non-Replicating Viral Vector	Adenovirus type 26 vector (first dose)Adenovirus type 25 vector (second dose)	2	0,28 days	IM